GLP1R and diabetes mellitus: According to the American Diabetes Association guidelines from 2023, GLP-1 RAs, especially liraglutide, dulaglutide, and semaglutide, were associated with beneficial renal outcomes in CV outcome trials; these renal benefits were driven by new onset or persistent macroalbuminuria outcomes [5].